Peter McLaughlin

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

Massimo Federico, Monica Bellei, Luigi Marcheselli et al. · Journal of Clinical Oncology · 2009 · 751 citations · Full text

Medicine, Clinical Sciences, Oncology +14

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Thomas A. Davis, Antonio J Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 2000 · 689 citations

Pharmacy, Hematology, Pharmacotherapy +15

Follicular lymphoma international prognostic index.

Pascal Roy, Philippe Colombat, Josephine M White et al. · PubMed · 2004 · 627 citations

Medicine, Hematology, Oncology +15

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)

WS Velasquez, Fernando Cabanillas, P. Salvador et al. · Blood · 1988 · 581 citations · Full text

Medicine, Oncology, Pharmacotherapy +11